View Older Stories View More Recent Stories
-
Insmed (INSM) PT Raised to $110 at Stifel
-
Insmed (INSM) PT Raised to $114 at TD Cowen
-
Insmed (INSM) PT Raised to $121 at Jefferies
-
Truist on Insmed (INSM): 'TPIP Data Is a Clearing Event'
-
Leerink on Insmed (INSM) as Shares Surge 26pct: 'we continue to view INSM as a core Rare Disease/blockbuster platform'
-
Insmed (INSM) Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension
-
Mizuho updates U.S. top picks: Adds CVS Health, PayPal and Oracle
-
Leerink Partners Reiterates Outperform Rating on Insmed (INSM)
-
Jefferies Starts Insmed (INSM) at Buy
-
Insmed (INSM) Misses Q1 EPS by 7c, Beats on Revenue
-
Insmed (INSM) Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028
-
Insmed (INSM): New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
-
H.C. Wainwright Reiterates Buy Rating on Insmed (INSM)
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Cantor Fitzgerald Reiterates Overweight Rating on Insmed (INSM)
-
Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
-
RBC sees a buying opportunity in this biotech stock after a recent dip
-
H.C. Wainwright Reiterates Buy Rating on Insmed (INSM)
-
RBC Capital Reiterates Outperform Rating on Insmed (INSM), 'Literature Analysis Suggests TPIP Has A High Likelihood of Meaningful Activity'
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
Truist on Insmed (INSM): 'We See a Favorable Risk/Reward Profile'
-
Insmed (INSM) PT Raised to $110 at UBS
-
RBC Capital Starts Insmed (INSM) at Outperform
-
Insmed (INSM) Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
-
Insmed (INSM) PT Raised to $105 at UBS
-
Insmed (INSM) Misses Q4 EPS by 14c
-
Insmed (INSM) PT Raised to $96 at Mizuho
-
Insmed (INSM) price target raised to $97.00 at Stifel
-
Insmed (INSM): FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025
-
Truist Securities Reiterates Buy Rating on Insmed (INSM)
-
Truist Securities Reiterates Buy Rating on Insmed (INSM) as 'Preliminary Arikayce FY2024 Sales Exceed Guidance'
-
Barclays shares outlook for Biotech in 2025, names preferred stocks
-
Insmed (INSM) spreader of 3K contracts of January 70 and 80 calls
-
Increasing unusual call option volume: INSM PAGS REAL DLO ATOM CHAU GRAB SONO QBTS HNST
-
Insmed (INSM) PT Lowered to $88 at Mizuho
-
Insmed (INSM) Misses Q3 EPS by 7c ; Offers Guidance
-
Insmed (INSM) PT Raised to $100 at Truist Securities
-
TD Cowen Reiterates Buy Rating on Insmed (INSM)
-
Insmed (INSM): New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
-
Insmed (INSM) option IV flat amid wide 2024 price movement
-
Stifel Reiterates Buy Rating on Insmed (INSM)
-
Goldman Adjusts Monthly US Directors Cut Conviction List
-
H.C. Wainwright Reiterates Buy Rating on Insmed (INSM)
-
Insmed (INSM) PT Raised to $92 at Mizuho, 'continue to favor it as our top longer-term idea'
-
Insmed (INSM) PT Raised to $98 at TD Cowen
-
Insmed (INSM) Misses Q2 EPS by 70c ; Offers Guidance
-
RBC's biotech survey shows investors more bearish vs. last time
-
2Q24 U.S. biotech earnings preview
-
Mizuho Reiterates Outperform Rating on Insmed (INSM)
